Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
ATLANTA, March 03, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization, research and development of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 37th Annual Cowen Health Care Conference, to be held March 6-8, 2017 at The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Monday, March 6, 2017, at 4:40 PM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimeraciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 [email protected] cg.capital
